Chick-fil-A salads helped me lose 130 pounds — Rhode Island man claims
A man in Rhode Island has claimed that eating Chick-fil-A salads helped him lose more than 130 pounds.
Tom Carroll shared that for the last two years, the popular fast food chain has unexpectedly shaped his weight loss journey.
'Does it sound it sound crazy to eat one thing every single day from a restaurant? Yeah, it does. But to me, it was vital' Carroll, who's based in Lincoln, Rhode Island, told local NBC news station WJAR on Sunday (February 2).
He explained that a concerning series of health scares, including a visit to the emergency room due to chest pains, prompted his decision to make life changes. At the time, he weighed 360 pounds.
'I knew I never wanted to have a night like that again,' he explained. 'It was awful, terrible. And I knew I never wanted to put my wife through that again.'
One evening, during a regular trip to Chick-fil-A with his wife, Carroll opted for the Spicy Southwest Salad for the first time.
'I was almost blown away with how good it was,' he recalled. Since that visit, he's had the same salad every day for the past two years. As a result, he's now lost 132 pounds.
'I have my lunch salad from Chick-fil-A and then I have my homemade version of that salad for dinner,' he added.
As a dedicated customer at the fast food restaurant near him, he's become friendly with some of the workers who've supported his weight loss journey.
'It's all just worked out awesome,' he explained. 'I can't thank them enough.'
However, it isn't just the salad that has helped Carroll lose weight. He's also made some serious changes to his diet, including cutting out alcohol entirely.
As noted on Chick-fil-A's website, the Spicy Southwest Salad comes with slices of grilled chicken breast served on a 'fresh bed of mixed greens.' The dish — which is 680 calories – also includes grape tomatoes, blends of Monterey Jack and Cheddar cheeses, roasted corn, black beans, poblano chiles, and red bell peppers.
Following his two-year journey with the salad, Carroll wrote a Substack about his experience, titled: 'Chick-fil-A Saved My Life.'
In the post, he celebrated the fact that he's been able to keep off the 132 pounds he'd lost as of July 2024.
He also shared in the post that he's developed a regular workout routine.
'For the first time in a very long time, I felt like I had a long life ahead of me,' he wrote.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Barry Sanders reveals he suffered heart attack last year, hopes to raise awareness
Barry Sanders revealed in an interview with CBS Sports he suffered a heart attack last June during Father's Day weekend while on a recruiting visit for his son. At the time, the former Detroit Lions superstar running back publicly announced on social media he had experienced a heart-related "heath scare," although Sanders has since opened up about the medical emergency in "The Making of a Heart Attack," an A&E special that will premiere Saturday at 1 p.m. ET and will highlight the hidden risks of heart attacks and strokes. Advertisement "I couldn't believe it, honestly," Sanders, 56, told CBS Sports. "I thought it was like heartburn, but it just kind of persisted." Sanders explained in the interview that he woke up that day with a burning sensation in his chest. Before his son's recruiting visit wrapped, he drove himself to the emergency room, where tests indicated that Sanders' enzyme levels were alarmingly high and still increasing. A heart catheter procedure determined that Sanders had actually suffered a heart attack. "Of all things, I don't know why, that just never entered my mind," Sanders said, via CBS Sports. "I'm learning through this process that there aren't necessarily any warning signs, unless you do what we're encouraging people to do, which is to go the doctor, get tested for LDLC levels, or bad cholesterol. That's the only way to find out if you have high cholesterol. It's not something you're going to be able to feel. You don't have to fit a certain physical profile." Sanders' experience will be unpacked in the documentary, as will the stories of other heart attack and stroke survivors. Advertisement Sanders told CBS Sports his health has improved in the year since the incident, thanks to medication, dietary changes and enhanced exercise habits, such as more frequent walking. While everyone's heart health is different, Sanders is encouraging people to talk to their doctors about it. The Hall of Famer will always have a place in football lore, but now he's carving a space off the field as a heart-health advocate.
Yahoo
5 hours ago
- Yahoo
Barry Sanders reveals he suffered heart attack last year, hopes to raise awareness
Barry Sanders revealed in an interview with CBS Sports that he suffered a heart attack last June during Father's Day weekend while on a recruiting visit for his son. At the time, the former Detroit Lions superstar running back publicly announced on social media that he had experienced a heart-related "heath scare," although Sanders has since opened up about the medical emergency in "The Making of a Heart Attack," an A&E special that will premiere Saturday at 1 p.m. ET and will highlight the hidden risks of heart attacks and strokes. Advertisement "I couldn't believe it, honestly," Sanders, 56, told CBS Sports. "I thought it was like heartburn, but it just kind of persisted." Sanders explained in the interview that he woke up that day with a burning sensation in his chest. Before his son's recruiting visit wrapped, he drove himself to the emergency room, where tests indicated that Sanders' enzyme levels were alarmingly high and still increasing. A heart catheter procedure determined that Sanders had actually suffered a heart attack. "Of all things, I don't know why, that just never entered my mind," Sanders said, via CBS Sports. "I'm learning through this process that there aren't necessarily any warning signs, unless you do what we're encouraging people to do, which is to go the doctor, get tested for LDLC levels, or bad cholesterol. That's the only way to find out if you have high cholesterol. It's not something you're going to be able to feel. You don't have to fit a certain physical profile." Sanders' experience will be unpacked in the documentary, as will the stories of other heart attack and stroke survivors. Advertisement Sanders told CBS Sports that his health has improved in the year since the incident, thanks to medication, dietary changes and enhanced exercise habits such as more frequent walking. While everyone's heart health is different, Sanders is encouraging people to talk to their doctors about it. The Hall of Famer will always have a place in football lore, but now he's carving a space off the field as a heart health advocate.
Indianapolis Star
9 hours ago
- Indianapolis Star
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV.' While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable. 1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease, 2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults. 3 This approval was supported by results from Moderna's Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATION mRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: Have any allergies Had a severe allergic reaction after receiving a previous dose of any other vaccine Have a fever Have a bleeding disorder or are on a blood thinner Are immunocompromised or are on a medicine that affects your immune system Have received any other RSV vaccine Have ever fainted in association with an injection How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Side effects that have been reported in clinical trials with mRESVIA include: Injection-site reactions: pain, underarm swelling or tenderness in the same arm of the injection, swelling (hardness), and redness Fatigue, headache, muscle pain, joint pain, chills, nausea or vomiting, fever and hives These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc.
